Literature DB >> 26324262

Analytical and functional determination of polymyxin B protein binding in serum.

Henrietta Abodakpi1, Jie Gohlke1, Kai-Tai Chang2, Diana S-L Chow1, Vincent H Tam3.   

Abstract

To enhance our understanding of the pharmacological properties of polymyxin B, serum protein binding for polymyxin B1, B2, and B3 and for isoleucine-polymyxin B1 was evaluated. Using equilibrium dialysis and ultrafiltration, comparable protein binding was found in all 4 components of polymyxin B (92% to 99%). Protein binding in human serum was further assessed using a functional assay, the results of which were in general agreement with previous findings (approximately 90%).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26324262      PMCID: PMC4604353          DOI: 10.1128/AAC.01815-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

Review 2.  Significance of protein binding in pharmacokinetics and pharmacodynamics.

Authors:  Stephan Schmidt; Daniel Gonzalez; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

3.  A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies.

Authors:  Jie He; Song Gao; Ming Hu; Diana S-L Chow; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2013-01-22       Impact factor: 5.790

4.  Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.

Authors:  Andrea L H Kwa; Tze-Peng Lim; Jenny G H Low; JingGuo Hou; Asok Kurup; Randall A Prince; Vincent H Tam
Journal:  Diagn Microbiol Infect Dis       Date:  2007-10-04       Impact factor: 2.803

  4 in total
  3 in total

1.  Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.

Authors:  Visanu Thamlikitkul; Yanina Dubrovskaya; Pooja Manchandani; Thundon Ngamprasertchai; Adhiratha Boonyasiri; Jessica T Babic; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Shixing Zhu; Jiayuan Zhang; Zhihua Lv; Peijuan Zhu; Charles Oo; Mingming Yu; Sherwin K B Sy
Journal:  Clin Pharmacokinet       Date:  2022-08-10       Impact factor: 5.577

3.  External evaluation of published population pharmacokinetic models of polymyxin B.

Authors:  Ya-Qian Li; Kai-Feng Chen; Jun-Jie Ding; Hong-Yi Tan; Nan Yang; Ya-Qi Lin; Cui-Fang Wu; Yue-Liang Xie; Guo-Ping Yang; Jing-Jing Liu; Qi Pei
Journal:  Eur J Clin Pharmacol       Date:  2021-08-03       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.